Hormonal
Intermittent hypoxia, the hallmark of Obstructive Sleep Apnoea Syndrome (OSAS), preferentially activates inflammatory transcription factors (specifically NF-kB and AP-1) over adaptive pathways, leading to endothelial dysfunction and increased cardiovascular risk.
If you have Obstructive Sleep Apnoea, treating it with CPAP is critical for your heart health, not just your energy levels. The repeated drops in oxygen during sleep trigger inflammation that damages your blood vessels. Effective CPAP therapy has been shown to significantly reduce these inflammatory markers (like TNFa) and improve endothelial function, thereby lowering your long-term risk of heart disease and stroke.
Intermittent hypoxia, the hallmark of OSAS, results in activation of pro-inflammatory transcription factors such as nuclear factor kappa B (NF-kB) and activator protein (AP)-1. These promote activation of various inflammatory cells... with the downstream consequence of expression of pro-inflammatory mediators that may lead to endothelial dysfunction.
Why this rating
Strong evidence from multiple cell culture, animal, and human studies, though the paper notes some conflicting results regarding specific markers like CRP and IL-6 due to obesity confounding.
Source
Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?
Stephen J. Ryan et al. · Postgraduate Medical Journal · 2009
DOI 10.1136/thx.2008.105577
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →